RxDoctor Payments Data

Mark St Lawrence, PA

Physician Assistant · Jacksonville, FLNPI 1962446377

Payments from drug & device makers

$11,544in general payments, 2019–2025

Across 556 payments — averaging $20.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Lilly USA, LLC$1K
  • AbbVie$875
  • GSK$708
  • AstraZeneca$609
  • plus $6K from 45 others

What the payments were for

  • Consulting fees$8007%
  • Travel & lodging$1972%
  • Food & beverage$10,54791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,544 in reported general payments places this provider in the 95th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$17,631
Medicare patients
162
Services billed
1,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$79,992
MounjaroTirzepatide36$41,631
EliquisApixaban31$33,813
JardianceEmpagliflozin21$16,176
TrulicityDulaglutide14$15,292
EntrestoSacubitril/Valsartan14$11,042
JanuviaSitagliptin Phosphate13$9,793
XareltoRivaroxaban13$8,399
Diclofenac Sodium22$3,215
Albuterol Sulfate HfaAlbuterol Sulfate75$2,803
Omeprazole147$2,592
Gabapentin85$1,785
Rosuvastatin Calcium167$1,635
Humalog Kwikpen U-100Insulin Lispro13$1,620
Ventolin HfaAlbuterol Sulfate14$1,579

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,364$79,99274 claims
Lilly USA, LLCMounjaro, Trulicity$1,011$56,92350 claims
PfizerEliquis$547$33,81331 claims
Boehringer IngelheimJardiance$357$16,17621 claims
NovartisEntresto$71$11,04214 claims
MerckJanuvia$251$9,79313 claims
Johnson & JohnsonXarelto$268$8,39913 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$21$1,016146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →